Trials / Terminated
TerminatedNCT01189864
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,493 (actual)
- Sponsor
- Cxlusa · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication. The data generated by this study will not be submitted to the FDA to support commercialization of these riboflavin drops.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciprofloxicin or Vigamox or other. | Ciprofloxicin or Vigamox or other to be used qid till epithelialized. |
| DRUG | Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc) | Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op |
| DRUG | Steroid (FML, Pred Forte, Flarex, etc.) | Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks. |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2017-02-03
- Completion
- 2017-02-03
- First posted
- 2010-08-27
- Last updated
- 2018-10-12
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01189864. Inclusion in this directory is not an endorsement.